_part-5-brca-1-2-mutations-and-prostate-cancer.jpg "Part 5: BRCA 1 2 mutations and prostate cancer from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 85 sec
✓ Published: 23-Jul-2021
✓ Published: 23-Jul-2021
Description:
This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.nnThe BRCA genes are an important part of the repair process for the daily onslaught of DNA damage, any faults can mean mistakes start to build up in the DNA, which increases the chances of the cell becoming cancerous. nnThis video explores the role of BRCA 1 and 2 genes in the HRR pathway and how it induces prostate cancer. A
This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.nnThe BRCA genes are an important part of the repair process for the daily onslaught of DNA damage, any faults can mean mistakes start to build up in the DNA, which increases the chances of the cell becoming cancerous. nnThis video explores the role of BRCA 1 and 2 genes in the HRR pathway and how it induces prostate cancer. A
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_olaparib-continues-to-show-positive-results-in-advanced-ovarian-cancer-7-year-data.webp "Prof Paul DiSilvestro, speaks to ecancer about his Phase III SOLO1/GOG-3004 trial which studied the overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. nnPatients who were in response to first-line platinum-based chemotherapy received maintenance olaparib tablets 300 mg bid or pbo for up to 2 years or until progression. A descriptive analysis of OS, a secondary endpoint, was performed 7y after the l")
⏲ 2 min 53 sec ✓ 10-Sep-2022
_lschenkel-parp14-aacr-2020.webp "LSchenkel_PARP14 AACR 2020 from parp")
_gu-connect-eks-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice.webp "GU CONNECT EKS Incorporating PARP inhibitors into prostate cancer clinical practice from parp")
⏲ 47 min 2 sec ✓ 17-Nov-2022
_development-and-clinical-indications-of-parp-inhibitors.webp "Dr O’Connor speaks with ecancer about the development and application of PARP inhibitors.nnHe describes his research in treatment tolerability and the overlap of efficacy with observed PARP trapping,nnFor more on PARP inhibitors, watch our interview with Dr Elisabetta Leo here.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.nnhttps://ecancer.org/account/register.php")
_southboro-lab-spinning-top.webp "South Side and Peterboro teachers have come together to create a video on how to make a spinning top. The Forces in Motion video is part of the family event during PARP month.")
_domenica-lorusso-md-phd-on-recurrent-ovarian-cancer-treatment-update.webp "Domenica Lorusso, MD, PhD, of the Instituto Nazionale Dei Tumori, discusses the role of PARP inhibitors in ovarian cancer treatment and guideline recommendations.")
⏲ 1 min 66 sec ✓ 23-Oct-2018
_13-14-parp-fox-reads.webp "This video is about 13_14 PARP Fox reads")
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.webp "Prof Kurt Miller (Benjamin Franklin Medical Centre, Berlin, Germany) and Prof Bertrand Tombal (Cliniques Universitaire Saint Luc, Belgium) share their thoughts on the genomic data and its implications for prostate cancer treatment presented from day 1 at ASCO. They emphasise that taking a detailed family history of any breast cancer, ovarian cancer as well as prostate cancers is a vital first step for new patients. nnGenetic counselling for ‘healthy’ family members needs to be considered alo")
⏲ 10 min 0 sec ✓ 03-Jun-2018
_olaparib-continues-to-show-positive-results-in-advanced-ovarian-cancer-7-year-data.jpg)
_lschenkel-parp14-aacr-2020.jpg)
_gu-connect-eks-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice.jpg)
_development-and-clinical-indications-of-parp-inhibitors.jpg)
_southboro-lab-spinning-top.jpg)
_domenica-lorusso-md-phd-on-recurrent-ovarian-cancer-treatment-update.jpg)
_13-14-parp-fox-reads.jpg)
_asco-2018-integrating-genomic-data-throughout-treatment-for-prostate-cancer.jpg)
![[+]](/images/menu.gif){kind=small}